Sartorius Stedim Biotech SA / Key word (s): Expansion Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France 17-Jun-2025 / 16:00 CET/CEST ...

Sartorius Stedim ... and cell analysis platforms. The company complements this offering with consumables—bioreactor bags, filters, tubing, containers, and cell culture media—essential for ...

The acquisition of MatTek aligns with Sartorius Stedim Biotech SA (SDMHF)'s innovation strategy, enhancing its portfolio with advanced cell models and AI analytics. Strong cash flow allowed the ...

With regard to its portfolio, Sartorius Stedim Biotech again expanded its product offering for biologics process development and manufacturing with a series of market launches. In addition to new ...

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry ... two GMP suites for implementing novel manufacturing processes. ”Cell and gene therapies and other novel treatments ...

In 2025, Sartorius Stedim Biotech will add two multi-modality GMP suites, operating on Sartorius workflows and equipment. The suites will allow customers to extend their process development ...

CEO of Sartorius Stedim Biotech; Maurice Phelan, President of Sartorius North America; Yvonne Hao, Massachusetts Secretary of Economic Development. "Cell and gene therapies and other novel ...

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius ... filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements ...

from private investors to strengthen its activities supplying cell and gene therapy companies. October 19, 2022 Sartorius shares drop as it tempers 2022 revenue ambitions Franco-German lab ...

Good day and welcome to the Sartorius and Sartorius Stedim Biotech Conference Call ... our very focused efforts to build a portfolio of Cell Culture Media and critical materials, which are used ...

Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors. The deal would bolster ...